Drug name - Restasis

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8648048 ALLERGAN Methods of providing therapeutic effects using cyclosporin components Aug, 2024

(1 year, 10 months from now)

US8633162 ALLERGAN Methods of providing therapeutic effects using cyclosporin components Aug, 2024

(1 year, 10 months from now)

US9248191 ALLERGAN Methods of providing therapeutic effects using cyclosporin components Aug, 2024

(1 year, 10 months from now)

US8685930 ALLERGAN Methods of providing therapeutic effects using cyclosporin components Aug, 2024

(1 year, 10 months from now)

US8629111 ALLERGAN Methods of providing therapeutic effects using cyclosporin components Aug, 2024

(1 year, 10 months from now)

US8642556 ALLERGAN Methods of providing therapeutic effects using cyclosporin components Aug, 2024

(1 year, 10 months from now)

US8292129 ALLERGAN Dispensing device Feb, 2031

(8 years from now)

US8561859 ALLERGAN Dispensing device Apr, 2032

(9 years from now)

US9676525 ALLERGAN Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids Feb, 2034

(11 years from now)

US9669974 ALLERGAN Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids May, 2034

(11 years from now)

Drugs and Companies using CYCLOSPORINE ingredient

Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).; Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).

Dosage: EMULSION;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.05% EMULSION;OPHTHALMIC Prescription

availability in other generic markets.

Click on the highlighted region to filter.